News · 26 weeks71-83%
2025-12-142026-06-07
Mix1690d
- Other6(38%)
- Insider4(25%)
- Leadership3(19%)
- Offering1(6%)
- SEC Filings1(6%)
- Analyst1(6%)
Latest news
25 items- ANALYSTH.C. Wainwright resumed coverage on AnaptysBio with a new price targetH.C. Wainwright resumed coverage of AnaptysBio with a rating of Buy and set a new price target of $95.00
- PRAnaptys Announces First Quarter 2026 Financial Results and Provides Business UpdateCompleted spin-off of First Tracks Biotherapeutics, Inc., its former biopharma operations businessNow exclusively manages the financial collaborations for Jemperli with GSK and imsidolimab with VandaAnnounced appointment of Chris Murphy as CFOAnnounced appointments of Susannah Gray, former CFO of Royalty Pharma, and Owen Hughes, current CEO of XOMA Royalty, to its Board of Directors SAN DIEGO, May 12, 2026 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (NASDAQ:ANAB), a company focused on managing the financial collaborations for Jemperli with GSK and imsidolimab with Vanda, today reported financial results for the first quarter ended March 31, 2026, and provided a business update. "Following the c
- PRAnaptys Appoints Chris Murphy as Chief Financial Officer and Owen Hughes to Board of DirectorsStrengthens Leadership Team and Board with additional business development, finance and royalty management expertise SAN DIEGO, May 11, 2026 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (NASDAQ:ANAB), a company focused on managing the financial collaborations for Jemperli with GSK and imsidolimab with Vanda, today announced the appointment of Christopher Murphy as Chief Financial Officer and Owen Hughes as a member of its Board of Directors. "We are excited to welcome Chris, who will be fully dedicated to Anaptys, and Owen, both of whom deepen our team's strong mix of expertise across finance, business development, royalty management and strategic transactions," said Daniel Faga, president and c
- PRAnaptys to Participate at the H.C. Wainwright 2nd Annual Royalty Company Virtual ConferenceSAN DIEGO, May 04, 2026 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (NASDAQ:ANAB), a company focused on managing the financial collaborations for Jemperli with GSK and imsidolimab with Vanda, today announced that Daniel Faga, president and chief executive officer of Anaptys, is scheduled to participate in a fireside chat at the H.C. Wainwright 2nd Annual Royalty Company Virtual Conference on Wednesday, May 6, 2026. The fireside chat is scheduled to begin at 1:30pm ET. To register for the conference, please visit https://hcwevents.com/royalty-company-conference. About AnaptysAnaptys manages the financial collaborations for Jemperli with GSK and imsidolimab with Vanda, with a focus on protecting
- PRVanda Pharmaceuticals announces the publication of "Efficacy and Safety of Imsidolimab for Generalized Pustular Psoriasis" in NEJM EvidenceWASHINGTON, April 28, 2026 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ:VNDA) today announced the publication of the original research article titled "Efficacy and Safety of Imsidolimab for Generalized Pustular Psoriasis" in New England Journal of Medicine (NEJM) Evidence1. The findings of this pivotal phase III study are included in the Biologics License Application (BLA) for imsidolimab for the treatment of Generalized Pustular Psoriasis (GPP), submitted to the U.S. Food and Drug Administration (FDA) with a target action date of December 12, 2026.ReferencesSmiesz
- PRDelaware Chancery Court Rules in Favor of Anaptys by Dismissing Tesaro's Anticipatory Breach ClaimRuling preserves current contracted royalty rates and rejects Tesaro's request for any royalty reductionTrial to adjudicate Anaptys' contract claims and right to seek reversion of Jemperli against Tesaro/GSK is scheduled for July 14-17, 2026 SAN DIEGO, April 24, 2026 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (NASDAQ:ANAB), a company focused on managing the financial collaborations for Jemperli with GSK and imsidolimab with Vanda, today announced that the Delaware Chancery Court has dismissed Tesaro's anticipatory breach of contract claim against Anaptys. The ruling agrees with Anaptys' position that it has never repudiated the Collaboration and Exclusive License Agreement ("Collaboration Agree
- PRAnaptys Completes Separation of First Tracks Biotherapeutics and Now Exclusively Manages GSK and Vanda Financial CollaborationsFocused on protecting and returning value of Jemperli and imsidolimab royalties to shareholdersLaunches with virtual model, including limited FTEs and minimal operating expenses, and approximately $140-$145 million in net cash SAN DIEGO, April 20, 2026 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (NASDAQ:ANAB), a royalty management company, today announced the completion of its spin-off of First Tracks Biotherapeutics, Inc., its former biopharma operations business. Anaptys will now exclusively manage the financial collaborations for Jemperli with GSK and imsidolimab with Vanda with a focus on protecting and returning the value of its royalties to shareholders. "Anaptys begins this next chapter
- INSIDERSEC Form 3 filed by new insider Gray Susannah3 - ANAPTYSBIO, INC (0001370053) (Issuer)
- INSIDERSEC Form 4 filed by Schmid John P.4 - ANAPTYSBIO, INC (0001370053) (Issuer)
- INSIDERSEC Form 3 filed by new insider Anaptysbio, Inc3 - ANAPTYSBIO, INC (0001370053) (Reporting)
- INSIDERSEC Form 4 filed by Faga Daniel4 - ANAPTYSBIO, INC (0001370053) (Issuer)
- SECAnaptysBio Inc. filed SEC Form 8-K: Regulation FD Disclosure8-K - ANAPTYSBIO, INC (0001370053) (Filer)
- PRFirst Tracks Biotherapeutics, the Planned Spin-Off of Anaptys, Secures Commitments of $145 Million in Private PlacementInclusive of $80 million in proceeds from private placement by leading investorsFirst Tracks Biotherapeutics to launch with $180 million in cash and two-year cash-runway SAN DIEGO, March 27, 2026 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (NASDAQ:ANAB) today announced that its planned spin-off, First Tracks Biotherapeutics, Inc. ("First Tracks Bio"), and EcoR1 Capital (the "Selling Stockholder") have entered into a purchase agreement with certain third-party investors for a $145 million private placement, before deducting placement agent fees and other expenses. In the transaction, First Tracks Bio is selling an aggregate of 5,791,478 shares of First Tracks Bio's common stock (the "Primary Sha
- PRAnaptys Board of Directors Approves Spin-Off of First Tracks BiotherapeuticsBoard sets spin-off distribution date for First Tracks Biotherapeutics: expected to occur April 20, 2026, pre-marketStockholders will receive one share of First Tracks Bio common stock for every one share of AnaptysBio common stock ownedFirst Tracks Bio initial cash balance of $180 million, inclusive of $80 million from private placement SAN DIEGO, March 27, 2026 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (NASDAQ:ANAB) today announced that its Board of Directors has approved the previously announced spin-off of First Tracks Biotherapeutics, Inc. ("First Tracks Bio"). The new company is expected to begin "regular-way" trading on the Nasdaq Stock Market LLC ("Nasdaq") on April 20, 2026, under the
- PRAnaptys Announces $100 Million Stock Repurchase Plan and Provides a Business UpdateAnaptys to spin-off biopharma operations into First Tracks Biotherapeutics, with a target distribution date of April 20, 2026Anaptys to manage the financial collaborations for Jemperli with GSK and imsidolimab with Vanda, with a focus on protecting and returning their value to shareholders, as well as an initial ~$140-$145 million in net cash and investmentsSusannah Gray, former CFO of Royalty Pharma, appointed to Anaptys' Board of Directors SAN DIEGO, March 27, 2026 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (NASDAQ:ANAB) today announced that its Board of Directors has authorized a Stock Repurchase Plan under which the company may repurchase up to $100,000,000 of the company's outstanding comm
- SECAmendment: SEC Form SCHEDULE 13G/A filed by AnaptysBio Inc.SCHEDULE 13G/A - ANAPTYSBIO, INC (0001370053) (Subject)
- SECSEC Form 10-K filed by AnaptysBio Inc.10-K - ANAPTYSBIO, INC (0001370053) (Filer)
- SECAnaptysBio Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits8-K - ANAPTYSBIO, INC (0001370053) (Filer)
- PRAnaptys Provides Update on Business Separation and Announces Fourth Quarter and Full Year 2025 Financial ResultsSpin-off of biopharma operations into a public company to be called "First Tracks Biotherapeutics" on track for Q2 2026, potentially as early as late-AprilPhase 1b enrollment ongoing in celiac disease and trial cohort initiated in eosinophilic esophagitis for ANB033, a CD122 antagonistGSK announced strong commercial performance for Jemperli, growing >13% quarter-over-quarter to $343 million in Q4 2025, implying a ~$1.4 billion annualized run rateExpect to achieve >$390 million in annualized Jemperli royalties payable to Anaptys at GSK's peak sales guidance of >$2.7 billion as early as 2029Year-end 2025 cash and investments of ~$311 million SAN DIEGO, March 03, 2026 (GLOBE NEWSWIRE) -- Ana
- PRVanda Pharmaceuticals Announces FDA Acceptance of Biologics License Application Filing for Imsidolimab for the Treatment of Generalized Pustular PsoriasisWASHINGTON, Feb. 25, 2026 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ:VNDA) today announced that the U.S. Food and Drug Administration (FDA) has accepted the filing of its Biologics License Application (BLA) for imsidolimab for the treatment of Generalized Pustular Psoriasis (GPP), with a target action date of December 12, 2026. GPP is a rare, chronic, life-threatening autoinflammatory skin disorder characterized by sudden flares of widespread pustules, erythema, and systemic symptoms such as fever and fatigue. The pathogenesis of GPP is increasingly understood th
- INSIDERCHIEF LEGAL OFFICER Loumeau Eric J exercised 10,000 shares at a strike of $29.70 and sold $540,000 worth of shares (10,000 units at $54.00) (SEC Form 4)4 - ANAPTYSBIO, INC (0001370053) (Issuer)
- SECSEC Form 144 filed by AnaptysBio Inc.144 - ANAPTYSBIO, INC (0001370053) (Subject)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by AnaptysBio Inc.SCHEDULE 13G/A - ANAPTYSBIO, INC (0001370053) (Subject)
- PRAnaptys Announces Participation at Upcoming Investor ConferencesSAN DIEGO, Feb. 05, 2026 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (NASDAQ:ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced that Daniel Faga, president and chief executive officer of Anaptys, and/or other members of its executive leadership team, are scheduled to participate in multiple upcoming investor conferences: Guggenheim Emerging Outlook: Biotech Summit 2026, New York, NY Format – Fireside chat and 1x1 investor meetingsDate and Time – Wednesday, Feb. 11, 2026 at 3:00pm ET Piper Sandler Virtual Novel Targets in Immunology Symposium, Virtual Format – Fireside chatDate and Time – Thursday, Feb. 12, 2026 at 12:30pm ET
- SECAmendment: SEC Form SCHEDULE 13G/A filed by AnaptysBio Inc.SCHEDULE 13G/A - ANAPTYSBIO, INC (0001370053) (Subject)
ANAB FAQ
7 questionsWhat does AnaptysBio Inc. do?
AnaptysBio, Inc., a clinical stage biotechnology company, engages in developing therapeutic product candidates for inflammation and immuno-oncology indications. The company's products include Imsidolimab, an IL-36R antibody that inhibits the interleukin-36 receptor for the treatment of various dermatological inflammatory diseases; ANB030, an anti-PD-1 agonist antibody program designed to augment PD-1 signaling through ANB030 treatment to suppress T-cell driven human inflammatory diseases; and ANB032, an anti-BTLA modulator antibody applicable to human inflammatory diseases associated with...Where does ANAB stock trade?
AnaptysBio Inc. (ANAB) is listed on NASDAQ.What sector and industry is ANAB in?
AnaptysBio Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did AnaptysBio Inc. go public?
AnaptysBio Inc. (ANAB) completed its IPO in 2017.What are analysts saying about ANAB?
AnaptysBio Inc. has had 8 recent analyst actions on file. The most recent action was from H.C. Wainwright: Buy on 2026-06-10. Recent price targets range from $1900.00 to $3800.00.What companies are similar to ANAB?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), AZN (AstraZeneca PLC), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.). Compare ANAB side-by-side with any of them on Quantisnow.How can I track ANAB on Quantisnow?
Quantisnow aggregates AnaptysBio Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow ANAB to receive live email and push alerts on every new disclosure.